Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziltivekimab - Novo Nordisk

Next Previous
Search
Drug Profile

Ziltivekimab - Novo Nordisk

Alternative Names: COR 001; EX-6018; MEDI-5117; NN-6018; WBP-216

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer MedImmune; Novo Nordisk
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Cardiovascular therapies; Heart failure therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders; Heart failure
  • Phase I Kidney disorders
  • Discontinued Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 25 Jun 2024 Novo Nordisk initiates the phase III ARTEMIS trial for Cardiovascular disorders in Argentina, Australia, Brazil, Bulgaria, Canada, China, Czech republic, Denmark, France, Germany, Greece, India, Israel, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Poland, Spain, Turkey, United kingdom and the US (SC) (NCT06118281) (EudraCT-2023-506876-28)
  • 01 Apr 2024 Novo Nordisk initiates the phase III ATHENA trial for Heart failure in Argentina, Australia, France, Malaysia, Spain (SC) (NCT06200207)
  • 01 Apr 2024 Phase-III clinical trials in Heart failure in Czech Republic, India, United Kingdom (SC) (NCT06200207)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top